Shanghai Jmt-bio Inc.

This study tests whether a new combination of drugs (KN026 plus HB1801 and chemotherapy) works better than the current standard treatment (trastuzumab, pertuzumab, and chemo) for people with HER2-positive breast cancer that has been surgically removed. About 1800 adults with canc…

This early-phase trial is testing an experimental drug called JMT108, given alone or with other cancer drugs (pembrolizumab or ivonescimab), in people with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the right dose, and get…

This study tests an experimental drug called JMT108 in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to check if the drug is safe and helps shrink tumors. About 188 adults who have tried other treatments without success will receive JM…

This study tests a new injection called JMT202 in 48 Chinese adults with very high triglycerides (a type of fat in the blood). The goal is to see if it is safe and can lower triglyceride levels. Participants will receive either the drug or a placebo over several doses, and resear…

This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinkin…

This study tests a new drug called JMT203 in people with lung, pancreatic, or colorectal cancer who are experiencing cachexia (severe weight loss and muscle wasting). The drug is an antibody that targets a protein linked to appetite loss. The trial will enroll about 307 participa…

This early-phase trial is testing the safety and tolerability of a single dose of JMT206 in 44 healthy adults aged 18 to 60. Participants receive either the drug or a placebo injection, and researchers monitor for side effects and how the drug moves through the body. The goal is …